---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-015947"
form_type: "8-K"
ticker: null
cik: "0001783032"
company_name: "Elevation Oncology, Inc."
filed_at: "2023-09-22T23:59:59+00:00"
generated_at: "2026-06-10T09:47:46.010488+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elevation Oncology receives Nasdaq bid-price deficiency notice; director resigns

## Summary
- Nasdaq notified on Sep 19, 2023 that bid price below $1.00 for 30 consecutive days; company has until Mar 18, 2024 to regain compliance.
- To cure, closing bid must be at least $1.00 for 10 consecutive business days by Mar 18, 2024.
- Director Colin Walsh resigned effective Sep 21, 2023 citing other professional opportunities; no disagreement with company.
- Steven A. Elms appointed to fill Audit Committee vacancy left by Walsh's resignation.
- Company considering actions to regain compliance; no assurance of success or continued listing.

## SEC filing metadata
- accession: 0001558370-23-015947
- form_type: 8-K
- cik: 0001783032
- company_name: Elevation Oncology, Inc.
- filed_at: 2023-09-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783032/000155837023015947/0001558370-23-015947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783032/000155837023015947/elev-20230919x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-015947
- JSON: https://secwatch.observer/filing/0001558370-23-015947.json
- Plain text: https://secwatch.observer/filing/0001558370-23-015947.txt

## Key facts
- Listing & Compliance Notices
  Elevation Oncology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: September 19, 2023, Elevation Oncology, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market. Pursuant to N
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000155837023015947/0001558370-23-015947-index.htm
- Executive change
  Colin Walsh resigned as Director at Elevation Oncology, Inc..
  - Action: resigned
  - Role: Director
  source text: On September 21, 2023, Colin Walsh, Ph.D., notified the Company of his resignation from the Board of Directors of the Company (the "Board"), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000155837023015947/0001558370-23-015947-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.